Top Retinal Drugs Companies

Global Retinal Drugs Market size was valued at USD 21.86 Billion in 2024 and is poised to grow from USD 23.65 Billion in 2025 to USD 44.42 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026–2033).

The competitive landscape of the retinal drug market is marked by intense R&D, strategic acquisitions, and a race toward long-acting and gene-based therapies. Key players like Roche, Regeneron, and Novartis dominate with anti-VEGF therapies, while others like Sandoz and Coherus expand biosimilar portfolios. Merck’s acquisition of EyeBio and Astellas' purchase of Iveric Bio highlight growing M&A activity. Companies are also investing in implants and AI-driven diagnostics to boost adherence and outcomes. The landscape includes branded drugs, biosimilars, gene therapies, delivery innovations, and pipeline diversification—shaping a competitive, innovation-focused market poised for sustained growth. 'Roche Holding AG (incl. Genentech)', 'Regeneron Pharmaceuticals, Inc.', 'Novartis AG', 'Bayer AG', 'Allergan (AbbVie Inc.)', 'Alcon Inc.', 'Santen Pharmaceutical Co., Ltd.', 'MeiraGTx Holdings plc', 'Ocuphire Pharma, Inc.', 'Kodiak Sciences Inc.', 'Adverum Biotechnologies, Inc.', 'Oxurion NV', 'Graybug Vision, Inc.', 'Clearside Biomedical, Inc.', 'Outlook Therapeutics, Inc.', 'Iveric Bio (acquired by Astellas Pharma)', 'Sandoz (a Novartis spin-off for biosimilars)', 'Coherus BioSciences, Inc.', 'Biogen Inc.'

The growing number of cases involving retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) is one major factor driving growth. Worldwide, over 196 million people experienced AMD in 2020, expected to grow to 288 million by the year 2040; diabetic retinopathy impacts almost 188 million people and RVO affects almost 16.4 million people, all of which continue to build the overall pool of patients pursuing retinal therapies. Dementia, diabetes and lifestyle factors affecting retinal health due to aging populations, increased screen use, and improper diets are only increasing the amount of retinal health problems and the need to increase retinal health therapies. Since people are able to see an eye doctor and learn about their disease earlier than before and earlier in the disease process, the possibility for intervention is clearer; as a result, the increase in demand for anti-VEGF medications, corticosteroids, and gene therapies, for example, will only rise.

North America is a dominant continent in the retinal drugs market because of its advanced healthcare system, high innovation and research development investments, and concentration of important players within the pharmaceutical industry. North America is a region with fast adoption of new therapies and expedient regulatory processes via the FDA, which allows quicker approval time for drugs. There are a notably high number of age-related macular degeneration diseases (AMD), diabetic retinopathy, and other retinal diseases as a portion of the area's aging population, equipping them for a demand of newer therapies. Access to expensive biologics and anti-VEGF therapies is not only promoted by public insurance, but as private health insurance coverage is more prevalent and, with patient coverage is a certainty in the most considerable risks, it would also help. When you have leading academic partners and biotech firms steered towards experimenting with gene therapy and regenerative therapy, this also helps motivate industry output.